Artelo Biosciences, Inc.

ARTL ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $600.0K $2.3M $2.8M $6.9M $12.2M $5.8M $4.4M $337.4K
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $695.0K $2.6M $11.0M $18.3M $24.6M $2.3M $4.4M $396.4K
Property, Plant & Equipment — — — — — $246 $721 $563
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) $2.0M $2.0M $2.0M $2.0M $2.0M $2.0M $2.0M —
Total Assets $2.8M $4.7M $13.0M $20.4M $28.3M $4.4M $6.5M $397.0K
Liabilities
Accounts Payable — — — — — — — —
Total Current Liabilities $4.0M $1.8M $1.3M $998.0K $1.0M $501.0K $1.0M $532.0K
Long-Term Debt — — — — — — — —
Total Liabilities $4.1M $1.8M $1.3M $1.0M $1.1M $501.0K $1.0M $532.0K
Stockholders' Equity
Retained Earnings $-63.0M $-50.1M $-40.3M $-31.0M $-20.9M $-9.5M $-4.8M $-2.6M
Total Stockholders' Equity $-1.3M $2.9M $11.8M $19.4M $27.2M $8.4M $5.5M $-135.0K
← Newer Page 1 of 2 Older →